Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) does about 2.83M shares in volume on a normal day but saw 92048559 shares change hands in Monday trading. The company now has a market cap of 51.60M USD. Its current market price is $3.90, marking an increase of 48.29% compared to the previous close of $2.63. The 52 week high reached by this stock is $54.60 whilst the lowest price level in 52 weeks is $2.40. The script in recent trading has seen the stock touch a high of $4.94 and a low of $3.35.
Sonnet BioTherapeutics Holdings Inc. (SONN) has a 20-day trading average at $3.03 and the current price is -92.86% off the 52-week high compared with 62.50% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.32 and its 200-day simple moving average is $9.88. If we look at the stock’s price movements over the week, volatility stands at 15.20%, which increases to 15.59% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 63.89 to suggest the stock is neutral.
1 analysts observing the Sonnet BioTherapeutics Holdings Inc. (SONN) stock have set the 12-month price targets for the company’s shares at between $7.00 and $7.00. The median price target is 44.29% away from the current levels at $7.00.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The current price level is 31.38%, 17.53%, and -60.86% away from its SMA20, SMA50, and SMA200 respectively, with the SONN price moving below the 50-day SMA on August 24. Sonnet BioTherapeutics Holdings Inc. (SONN) stock is up 43.38% over the week and 33.56% over the past month. Its price is -74.58% year-to-date and -70.59% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2019, with the company’s earnings per share (EPS) of -$20.8 below consensus estimates by -$14.04. In addition, estimates put the company’s current quarterly revenue at an average of $9.65 million.
Its 12-month price target is $7.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $7.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $7.00.
Outstanding shares total 13.23M with insiders holding 0.77% of the shares and institutional holders owning 0.52% of the company’s common stock. The company has a return on investment of -436.50%. The beta has a value of 0.99. Price to sales ratio is 1.84.
According to a U.S. Securities and Exchange Commission filing, iShares Tr – Micro Cap ETF has reduced its position in Sonnet BioTherapeutics Holdings Inc. (SONN) to 14,966 shares, mirroring a recent drop by 0.00%. iShares Tr – Micro Cap ETF dumped 0.0 shares of Sonnet BioTherapeutics Holdings Inc. common stock bringing its total worth to about $61510.0 at the end of recent close, SEC documents show. iShares Tr – Micro Cap ETF isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 871 shares worth $3580.0. Fidelity Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.00% position in Sonnet BioTherapeutics Holdings Inc. thanks to 347.0 shares amounting to $1426.0.